ORCIPRENALINE SYRUP

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ORCIPRENALINE SULFATE

Pieejams no:

AA PHARMA INC

ATĶ kods:

R03CB03

SNN (starptautisko nepatentēto nosaukumu):

ORCIPRENALINE

Deva:

2MG

Zāļu forma:

SYRUP

Kompozīcija:

ORCIPRENALINE SULFATE 2MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

250ML

Receptes veids:

Prescription

Ārstniecības joma:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0102598001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

1997-11-10

Produkta apraksts

_ORCIPRENALINE (Orciprenaline Sulfate Syrup) _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 23 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ORCIPRENALINE
Orciprenaline Sulfate Syrup
Syrup 2 mg/mL and Oral
House Standard
Beta-Adrenergic Agonist
Bronchodilator
AA PHARMA INC.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
www.aapharma.ca
Submission Control Number: 267347
_ _
_ _
Date of Initial Authorization:
April
17, 2014
Date of Revision:
OCT
11,
2022
_ORCIPRENALINE (Orciprenaline Sulfate Syrup) _
_ _
_ _
_ _
_ _
_ _
_ Page 2 of 23 _
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions
10/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
...................................................................................................................
4
1.1
Pediatrics
..........................................................................................................................
4
1.2
Geriatrics
..........................................................................................................................
4
2
CONTRAINDICATIONS
......................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.....................................................................................
5
4.1
Dosing Considerations
......................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................................................................ 5
4.4
Administration
.............................................